On March 23, 2026, William Blair initiated coverage of Eupraxia Pharmaceuticals (NasdaqCM:EPRX) with an “Outperform” recommendation. The average one-year price target for the company is projected at $10.82 per share, indicating a potential 47.48% increase from its last closing price of $7.34 per share. The price targets range from a low of $10.23 to a high of $11.65.
As of February 25, 2026, Eupraxia Pharmaceuticals has a projected annual revenue of $46 million and an expected non-GAAP EPS of -$0.54. In the last quarter, 38 funds reported positions in the company, an increase of 26.67%, with total institutionally owned shares rising 4.96% to 13,449K shares.
Among institutional shareholders, Beutel, Goodman & Co owns 3,709K shares (6.03% ownership), while Scotia Capital increased its stake to 1,286K shares (2.09% ownership), reflecting a 25.36% increase in portfolio allocation.
